Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
The global market for arthroscopy products and sports medicine implants is expected to reach $9.0bn by 2023, a CAGR of 4.2% from $7.3bn in 2018, driven in part by the rising availability of arthroscopy at ambulatory surgery centers in many countries, expanding indications for arthroscopic repair, patient preference for minimally invasive procedures and advanced techniques.
Latest From Market Intelligence
At this year's annual American Association of Neurological Surgeons (AANS) conference, medical device makers demoed high-tech digital solutions for neurosurgeons. See what Synaptive Medical's president, Cameron Piron, said about its surgical planning software.
This year's annual American Association of Neurological Surgeons conference offered neurosurgeons and allied health professionals five days of clinical trial news, seminars and live-streaming videos to learn about the latest developments in their field. Medtech Insight had an ear close to the ground, posting Tweets on some of the latest technologies, including robotic-assisted microscopes, showcased by exhibiting companies. Here is a round-up of the best of the Tweets and updates from company executives.
Global sales of cochlear implants are expected to reach $1.8bn by 2023, at a CAGR of 8.6%, driven by miniaturized yet powerful systems that help the growing number of people with severe hearing loss reconnect with the world around them. This market is led by Cochlear Ltd. and two other players, Advanced Bionics/Sonova and MED-EL, which continue to innovate and expand into key markets, such as older adults. Lack of awareness and high cost remain some of the biggest challenges.
The global market for blood gas monitoring systems is expected to grow 6.1% annually to reach $4.9bn in 2023, driven by the rising prevalence of chronic diseases, the aging population, and pressure on medical device makers to introduce smart devices that improve outcomes while reducing cost of care.
Liquid biopsy is a rapidly developing noninvasive technology for the early detection of cancer. Multiple companies have entered clinical testing, using mostly blood to detect circulating tumor cells and/or circulating tumor DNA. But urine and even cerebral spinal fluid are promising liquids too. Regardless of the fluid, testing costs a fraction of a traditional, invasive tissue biopsy and offers much quicker results.
The global market for breast cancer imaging and biopsy technologies is expected to reach $5.8bn by 2022, a CAGR of 5.9%, driven by innovation technologies and machine-learning tools that serve as "second readers" to help radiologists triage images and find cancers. Many radiologists believe that mammography will remain the most widely used screening tool, but that digital breast tomosynthesis will ultimately become the gold standard. Here's a close look at the overall breast imaging and biopsy market, highlighting different modalities and key players, and offering the real-world use perspective from three radiologists at Kaiser Permanente, San Diego.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.